Zomedica (ZOM) was founded in 2015 in Ann Arbour, Michigan. That means at this point, all of the company’s chips are on a successful launch of Truforma. Zomedica expects to begin commercial sales of TRUFORMA on March 30, 2021. Schilk joined Zomedica in 2018, and has been essential in building the internal sales organization in anticipation of the commercial release of TRUFORMA™. Following the launch, two more assays are expected to be added to the technology in 2021. Qorvo has been awarded a $24.4 million contract with the National Institutes of Health (NIH) through the Rapid Acceleration of Diagnostics (RADxSM) initiative. The potential of ZOM stock’s performance and sales of TRUFORMA in 2021. So, the company is making changes to ensure that its first launch goes successfully in the market. Right now, Zomedica’s focus is on the final development of the two initial Truforma diagnostic panels. The platform will hit the market on March 30, and ahead of the product’s debut, the company has also just nabbed a vital distribution deal. Zomedica Stock Is Still a Risk. Zomedica (ZOM) expects to begin commercial sales of TRUFORMA on March 30, 2021. Recently, ZOM said that it plans to launch its TRUFORMA diagnostics platform in March of 2021. Moreover, the company has just appointed a new CEO, Robert Cohen, who has previously served Zomedica as its interim CEO. This is either going to go really great for investors or go extremely sour for them. And that's the big news here. Zomedica has an unrivaled market opportunity within the $2.6B global companion animal diagnostics market with that expected to grow at a CAGR of nearly 10% through 2024 to $10B and beyond. Zomedica (ZOM) expects to begin commercial sales of TRUFORMA on March 30, 2021. TRUFORMA ™ is Zomedica’s flagship product that is expected to launch in the near term alongside a digital customer data platform which will connect the line of products and the company’s diagnostic pipeline. Rob’s successful track record in launching medical devices is perfectly aligned for Zomedica’s needs as we complete the development of our TRUFORMA™ platform and achieve its commercial launch. “This strategic change will focus the entire Zomedica team on the completion of the development and the beginning of commercialization of TRUFORMA™. Zomedica’s Truforma tool provides quick and effective diagnosis of common illnesses found in dogs and cats including adrenal and thyroid disorders. And in late January, Zomedica signed a deal with Miller Veterinary Supply for the distribution of TRUFORMA. Zomedica Corp.(NYSE:ZOM): Pet care stocks have been on a solid run of late as homebound lifestyles have caused more Americans to adopt pets. According to Zomedica, the technology’s high precision means veterinarians could diagnose companion animals for conditions such as thyroid and adrenal disorders without requiring a reference lab confirmation. Cohen added, “This is a momentous day for Zomedica, our shareholders, the veterinarians we serve, and the companion animals in their care.” With the commercial launch of TRUFORMA and new capital being raised, now is the time for Zomedica to scale things out. About Zomedica Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for dogs and cats by focusing on the unmet needs of clinical veterinarians. That’s excellent news if you own ZOM stock. The announced their first official sale of their product on March 16th but the official launch is on the 30th. Zomedica has also been appointed different people to leadership roles in advance of the commercial launch. While it turns out Baskin was paid to promote the stock, there is another upcoming and more tangible catalyst for investors to get behind; this is due to the upcoming launch of Truforma, Zomedica’s point-of-care (POC) diagnostic device for the detection of thyroid disease in dogs and cats and adrenal disease in dogs. The launch of the TRUFORMA ® platform is an exciting and disruptive milestone in the veterinary diagnostics testing industry that will raise the standard of … About Zomedica (ZOM) Based in Ann Arbor, Michigan, Zomedica (ZOM) is a veterinary health company creating products for dogs and cats by focusing on the unmet needs of clinical veterinarians. Zomedica is in the process of commercializing its Truforma device, which measures cortisol levels in dogs and cats using bulk acoustic wave technology. ANN ARBOR, Mich., March 16, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, yesterday recorded the first veterinarian sale of TRUFORMA® and officially entered commercialization. Zomedica stock was up by 13% at close on Wednesday. The answer is simple. It is expected that Zomedica will launch its innovative diagnostic tool—TRUFORMA—on March 31, 2021. Zomedica’s flagship and first product is its pet diagnostic platform, Truforma. With any penny stock a range of outcomes is possible. Zomedica is making tremendous strides to launch its first companion pet diagnostics device, TRUFORMA™, to a market that has both demand and lucrative opportunities. Some investors who own the stock believed that the company can achieve huge profits through TRUFORMA platform, a veterinary diagnostics testing device. Zomedica is making tremendous strides to launch its first companion pet diagnostics device, TRUFORMA™, to a market that has both demand and lucrative opportunities. The veterinary industry is a massive one, and Zomedica teamed up with one of the largest distributors in the space for the launch of its product. There is also investor excitement around Zomedica’s upcoming launch of TRUFORMA — which is expected to arrive on March 30. Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V), announced today that it intends to focus on the final development and commercialization of TRUFORMA™, its inaugural point-of … Just like the sour patch kids. 605. The company's first product, a diagnostic tool called Truforma, is scheduled for commercial launch on March 31. Tangible catalyst behind surge is due to the upcoming launch of Truforma , Zomedica’s point-of-care (POC) diagnostic device for the detection of thyroid disease in dogs and cats and adrenal disease in dogs. This tool was expected to be released by the end of the month, so the company’s a bit ahead of schedule. With any penny stock a range of outcomes is possible. Shares of Zomedica rising as TRUFORMA launch grabs investor attention. Good luck to everyone, do what you think is best for you. The post Zomedica’s Early Launch Is Music to Shareholders’ Ears appeared first on InvestorPlace. ANN ARBOR, Mich., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today announced that, with the hiring of Debra Rock to lead the Company’s Marketing Department, its internal commercial leadership team is complete. Zomedica Pharmaceuticals shares … Against this backdrop, we think shares of veterinary diagnostic company Zomedica Corp. (ZOM) are well-positioned to gain ahead of the company’s forthcoming launch of its flagship Truforma point-of-care diagnostic platform in March. One of the triggers has to do with Zomedica CEO issuing a Shareholder Letter as TRUFORMA nears commercialization. ANN ARBOR, Mich., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today announced the appointment of Robert Cohen as Chief Executive Officer effective January 1, 2021. Zomedica is expected to complete validation studies for TRUFORMA™ during the fourth quarter of 2019 with a planned commercial launch as soon as practical after that. Zomedica Announces First Commercial Sale of Its Truforma® Platform. In my last article about Zomedica (NYSEAMERICAN: ZOM), I said that the March 30 launch of its Truforma diagnostic platform for dogs and cats couldn’t come soon enough. So this has clearly been a milestone that traders have kept track of. TRUFORMA is a point-of-care diagnostic device used for detecting thyroid disease in dogs and cats. 167. The launch of the TRUFORMA (R) platform is an exciting and disruptive milestone in the veterinary diagnostics testing industry that will raise the standard of … Rob’s successful track record in launching medical devices is perfectly aligned for Zomedica’s needs as we complete the development of our TRUFORMA™ platform and achieve its commercial launch. Zomedica expects to begin commercial sales of TRUFORMA on March 30, 2021.About Zomedica Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for dogs and cats by focusing on the unmet needs of clinical veterinarians. Zomedica expects to begin commercial sales of TRUFORMA on March 30, 2021. Zomedica (ZOM) in Focus: Stock Moves 7.2% Higher - www.zacks.com. Shares of Zomedica (ZOM) has seen an 87% increase in the green today, this is mostly in part due to the coming product launch in March, two months from now.. Zomedica sets March 30 th as the date of commercialization of their TRUFORMA platform, protected by approximately 70 issued and pending patents, the TRUFORMA platform uses Bulk Acoustic Wave (“BAW”) technology, developed by … The market certainly seems to like the execution of Zomedica thus far, and investors have bid up shares accordingly. TRUFORMA is a diagnostics platform that uses Bulk Acoustic Wave technology to provide a non-optical and fluorescence-free detection system and is protected by around 70 issued and pending patents. She is dedicated to keeping product innovations on track, within budget, and consistent with organizational goals in order to realize market launch objectives as quickly and profitably as possible.
Charlotte Hornets Nba 2k21,
Fashion United Facebook,
Jenni Rivera's Childhood Home Address,
August 32nd On Earth Soundtrack,
Reddit Stock Tracker And Analysis Spreadsheet,
The Magnificent Seven The Clash Reddit,